Document is current

Article History

Accepted: 16 July 2024

First Online: 12 August 2024

Declarations

:

: ZC receives research funding from AstraZeneca and consultancy fees from Roche, Lexicon Pharmaceuticals, Abiomed, and Kestra Medical Technologies. KD reports speaker and consultancy fees to institutions from AstraZeneca, Boehringer Ingelheim, and Abbott. JHH receives research funding from the NIA, Boehringer Ingelheim, and Merck. JMTM reports speaker and/or consultancy fees to institutions from Novartis, Boehringer Ingelheim, Moderna, Roche, and Novo Nordisk and receives personal grants from the Netherlands Heart Foundation and Netherlands Organization for Scientific Research (NWO). JL receives research funding from AstraZeneca, Volumetrix, Sensible Medical, and NIH and consulting fees from AstraZeneca, Abbott, Alleviant, Boehringer Ingelheim, Boston Scientific, CVRx, Edwards Lifesciences, Medtronic, Merck, Vascular Dynamics, VWave, and Whiteswell. JT reports grants and/or personal fees from 3ive labs, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Astra Zeneca, Novartis, Cardionomic, MagentaMed, Reprieve Inc., FIRE1, W.L. Gore, Sanofi, Sequana Medical, Otsuka, Abbott, Merck, Windtree Therapeutics, Lexicon Pharmaceuticals, Precardia, Relypsa, Regeneron, BD, Edwards life sciences, and Lilly. In addition, JMT has a patent treatment of diuretic resistance issued to Yale and Corvidia Therapeutics Inc., a patent method for measuring renalase issued to Yale, and a patent treatment of diuretic resistance pending with Reprieve Inc. SPC reports consulting with Boehringer Ingelheim, Aiphia, and Siemens and research support from PCORI, NIH, and Beckman Coulter.Authors JMTM and KD are Editorial Board Members of the journal.